pH dynamics
Continuous acid–base profile across every GI segment, capturing gastric output, bile and bicarbonate response, and colonic fermentation depth.
Precision medicine · Personalized nutrition
The first Digital Gut Twin™.
A living, in-vivo model of human physiology — pH, redox, core temperature, transit, and motility, measured continuously and fused into a personal twin that powers precision medicine and personalized nutrition.
pH
Continuous
ORP
Redox state
Temp
Core, in-gut
Motility
9-axis
The problem
Personalized medicine stops at the stomach.
The gut is the control surface for metabolism, drug absorption, hormonal cycling, immunity, and longevity — yet it remains the least-instrumented organ in modern medicine.
GLP-1 protocols, hormone therapy, nutrition plans, and longevity stacks are all titrated against the wrong signal: outcomes that arrive weeks late, or self-report. The biology that actually drives response — what happens inside you, in real time — is invisible.
The result is generic protocols, missed responders, and personalization that never gets past genotype and questionnaires.
The approach
We measure the gut from the inside, in real time.
ORP (redox state)
The electrochemical fingerprint of microbial metabolism. Reveals fermentation health, oxygen leakage, and dysbiosis signatures invisible to any stool test.
Core temperature
Circadian rhythm and digestive thermogenesis measured from the gut itself — the body's true central clock.
Transit & motility
Segmental transit times and peristaltic patterns from a 9-axis sensor, capturing not just how long but how variably food moves.
The Digital Gut Twin™
A model that learns you.
Raw sensor streams feed a layered model — first extracting 40–60 derived physiological features (gastric pH kinetics, ileocecal ORP delta, transit variability, circadian amplitude), then fusing them into a dynamic personal model that updates as you live, eat, dose, and sleep.
The result is the first computational substrate for personalization that actually works — across GLP-1 response, metabolic health, hormonal cycling, gut conditions, longevity protocols, and preventative care.
- 1SensorspH · ORP · Temp · 9-axis
- 2Feature Extraction40–60 derived features
- 3Personal ModelLiving, updating twin
- 4RecommendationsSpecific. Grounded.
What it powers
One platform. Many indications.
The Digital Gut Twin™ is a horizontal substrate. The same continuous physiology that explains a GLP-1 responder also explains an IBD flare, a perimenopausal metabolic shift, or the earliest signal of decline.
See all use casesNow
GLP-1 optimization
Adherence, side-effect mitigation, efficacy, and maintaining results after taper.
Core
Metabolism & weight
Glycemic response, fermentation patterns, and the gut–liver axis.
Core
Gut health & IBD
IBS, IBD, SIBO, and functional GI disorders measured continuously, not retrospectively.
Expanding
Women's health
Cycle, perimenopause, and HRT response read through gut physiology.
Long horizon
Longevity
Circadian alignment, inflammation load, and metabolic flexibility tracked over years.
Long horizon
Preventative care
Earliest detectable shifts in physiology — before disease, before symptoms.
Why now
The convergence has arrived.
01
Ingestible sensor capsules have crossed the cost and miniaturization threshold for consumer use.
02
GLP-1s have made an entire generation expect — and pay for — measurable, personalized metabolic outcomes.
03
AI models can now fuse multi-channel time-series biology into actionable, individualized guidance.
Opportunity
A foundational layer for precision medicine.
GLP-1 is a $150B category by 2030 with no measurement layer. Personalized nutrition is racing past $90B, longevity past $40B, and women's health is one of the fastest-growing pharma segments of the decade. Each is bottlenecked by the same missing input: continuous, in-vivo physiology. The first company to make the gut measurable in real time owns the substrate the entire category has been waiting for.
$150B
GLP-1 category by 2030
$90B
Personalized nutrition by 2030
FAQ
Questions investors and scientists ask us.
Stool tests describe what exits the colon after the fact. We measure the gut as a living, dynamic organ — pH, redox, temperature, and motility as they happen, in every segment, across days and meals. It's the difference between a single photograph and continuous video.
The capsule is a passively transiting ingestible sensor — comparable in form factor and safety profile to FDA-cleared motility and pH capsules already in clinical use. It records continuously through the GI tract and is excreted naturally within 24–48 hours. We are pursuing a wellness-tier launch with a parallel clinical-grade regulatory track.
This is where most personalized health ventures fail — they generate data but lack a coherent framework to act on it. We ground our recommendation engine in a phenotyping system that has survived millennia of clinical observation: the Ayurvedic constitutional framework of Vata, Pitta, and Kapha.
Stripped of metaphysics, this is a three-axis classification of digestive, thermoregulatory, and motility phenotypes — essentially an early, observation-derived clustering of gut physiology. Modern sensor data lets us do what Ayurvedic physicians did by hand for two thousand years, but with quantitative precision: place each user on a continuous (Vata, Pitta, Kapha) probability vector based on their actual measured pH dynamics, ORP gradients, transit variability, and circadian temperature signatures.
From there, recommendations become specific and grounded — not generic. We use ancient pattern recognition as the interpretive layer; modern biosensing as the measurement layer.
A multi-arm clinical study pairs continuous capsule data with practitioner-blinded constitutional assessments, sensor-derived feature clustering, and longitudinal outcome tracking against established GI and metabolic endpoints.
Initially: GLP-1 users seeking to optimize response and maintain results, and high-agency consumers and patients with metabolic, hormonal, or gut conditions current tools cannot resolve. Long-term: a foundational layer for precision medicine, personalized nutrition, and longevity.
Wellness-tier launch first, using a non-diagnostic positioning consistent with comparable cleared ingestible devices. A clinical-grade follow-on pursues 510(k) indications for motility and functional GI disorders, with longitudinal data supporting expanded claims.
Team
Clinicians, biosensor engineers, and ML scientists.
Dr. Anika Rao
CEO & Co-founder
MD, PhD. Gastroenterologist, ex-Verily. Led ingestible sensor program at Stanford.
Dr. Léon Marchetti
CSO & Co-founder
PhD Biomedical Engineering, MIT. Twenty papers on in-vivo biosensing and microbial electrochemistry.
Priya Venkatesh
Head of ML
Ex-DeepMind health team. Time-series fusion across CGM, ECG and gut physiology.
Dr. James Okafor
Clinical Director
Functional GI specialist, formerly Mayo Clinic. Principal investigator on three motility trials.
The round
We're raising to build the first cohort.
A $6M seed round funds our pivotal clinical study, the sensor-manufacturing partnership, the first production-ready release of the Digital Gut Twin™ model, and the founding scientific team. It carries us to the cohort milestone that unlocks our Series A: 1,000 fully twinned users with longitudinal outcome data across GLP-1, metabolic, and gut indications.